Biologics, biosilimars, and biobetters: different terms or different drugs?

被引：10

作者：

Sharma, Ashish ^{[1
]}

Kumar, Nilesh ^{[1
]}

Kuppermann, Baruch D. ^{[2
]}

Francesco, Bandello ^{[3
]}

Loewenstein, Anat ^{[4
,5
]}

机构：

[1] Lotus Eye Hosp & Inst, Dept Vitreoretina, Coimbatore, TN, India

[2] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA

[3] Univ Vita Salute, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy

[4] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel

[5] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

来源：

EYE | 2019年 / 33卷 / 07期

关键词：

TRASTUZUMAB EMTANSINE; BIOSIMILARS;

D O I：

10.1038/s41433-019-0391-5

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

引用

页码：1032 / 1034

页数：3

共 14 条

[1]

Andrei Stefan, 2018, Discoveries (Craiova), V6, pe81, DOI 10.15190/d.2018.1

[2]

Anour R, 2014, GABI J, V3, DOI 10.5639/gabij.2014.0304.039

[3] Biosimilar: what it is not [J].

de Mora, Fernando .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) :949-956

[4]

DePalma A, 2011, WILL BIOBETTERS BEAT

[5]

Dinwoodie N, 2011, BIOPHARM INT

[6] Biosimilar competition: lessons from Europe [J].

Grabowski, Henry ;

Guha, Rahul ;

Salgado, Maria .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (02) :99-100

[7] Progress in biopharmaceutical development [J].

Kesik-Brodacka, Malgorzata .

BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2018, 65 (03) :306-322

[8] Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer [J].

LoRusso, Patricia M. ;

Weiss, Denise ;

Guardino, Ellie ;

Girish, Sandhya ;

Sliwkowski, Mark X. .

CLINICAL CANCER RESEARCH, 2011, 17 (20) :6437-6447

[9]

Sharma A, RETINAL PHYS WET AMD

[10] Biosimilars in ophthalmology: "Is there a big change on the horizon?" [J].

Sharma, Ashish ;

Reddy, Prahalad ;

Kuppermann, Baruch D. ;

Bandello, Francesco ;

Lowenstein, Anat .

CLINICAL OPHTHALMOLOGY, 2018, 12 :2137-2143

← 1 2 →